XML 23 R8.htm IDEA: XBRL DOCUMENT v3.19.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Cash flows from operating activities:      
Net loss $ (96,967,830) $ (88,205,772) $ (73,740,339)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation 3,747,183 1,850,376 1,708,498
Amortization of intangible assets 1,249,584 1,618,665 1,377,466
Change in value of common stock warrants (360,795) (806,819) (127,554)
Stock-based compensation 10,654,622 13,070,962 10,479,135
Amortization of premiums on investments 72,561 319,845 266,290
Deferred taxes 0 (150,027) (849)
Loss on short-term investments 1,342,005 215,423 139,249
Loss on disposal of fixed assets 14,529 0 0
Loss (gain) on investment in affiliated entities 1,988,567 6,982,664 (1,110,787)
Gain on sale of intangible assets 0 (1,000,000) (1,000,000)
Changes in operating assets and liabilities:      
Accounts receivable 2,686,844 9,818,306 (8,521,899)
Accounts receivable from affiliated entities (251,964) 261,736 (714,908)
Prepaid expenses and other current assets 1,194,316 (851,847) (831,802)
Prepaid expenses and other current assets from affiliated entities 725,202 (333,583) (901,772)
Other assets (30,644) (526,207) (1,442,314)
Accounts payable and accrued expenses 550,407 2,829,807 6,367,965
Accrued clinical trial expenses (2,940,128) 2,243,503 3,767,906
Accounts payable and accrued expenses due to affiliated entities 50,849 (145,636) 907,532
Deferred revenue (1,016,836) (13,689,322) 1,527,686
Deferred revenue from affiliated entities (140,535) (319,876) (687,827)
Deferred rent (398,357) 3,608,881 (16,728)
Deferred grant funding 4,165,848 0 0
Deferred grant funding from affiliated entities 27,083 0 0
Other liabilities 87,333 0 0
Net cash used in operating activities (73,550,156) (63,208,921) (62,555,052)
Cash flows from investing activities:      
Purchases of investments (88,155,046) (95,700,144) (57,317,671)
Maturities of investments 132,659,976 77,162,902 76,528,030
Purchases of capital assets (2,085,022) (10,293,902) (2,738,470)
Proceeds from sale of intangible assets 0 1,000,000 1,000,000
Purchase of intangible and other assets 0 0 (1,200,000)
Net cash provided by (used in) investing activities 42,419,908 (27,831,144) 16,271,889
Cash flows from financing activities:      
Proceeds from issuance of common stock and warrants, net of issuance costs 29,227,776 94,347,922 6,295,761
Proceeds from stock option and warrant exercises, net of tax payments 1,809,526 1,342,250 1,640,740
Expenses from other financing activities 0 0 (149,559)
Net cash provided by financing activities 31,037,302 95,690,172 7,786,942
Increase (decrease) in cash and cash equivalents (92,946) 4,650,107 (38,496,221)
Cash and cash equivalents, beginning of period 23,786,579 19,136,472 57,632,693
Cash and cash equivalents, end of period 23,693,633 23,786,579 19,136,472
Supplemental disclosure of non-cash activities      
Common stock issued for purchase of Bioject 0 0 4,300,000
Change in amounts accrued for purchases of property and equipment 694,472 851,204 164,923
Lease incentive recorded as fixed assets and deferred rent $ 0 $ 0 $ 523,856